T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming SVB Leerink Global Healthcare Conference in New York, New York.

Management is scheduled to present Thursday, February 27, 2020 at 11:00am ET. Interested parties may access a live and recorded webcast of the presentation on the “Investors” section of the company’s website at www.t2biosystems.com. 

About T2 Biosystems T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, and the T2Resistance™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including products for the detection of additional species and antibiotic resistance markers of sepsis pathogens, and tests for Lyme disease. 

Media Contact: Gina Kent, Vault Communications gkent@vaultcommunications.com 610-455-2763

Investor Contact: Philip Trip Taylor, Gilmartin Group philip@gilmartinIR.com 415-937-5406

T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From May 2020 to Jun 2020 Click Here for more T2 Biosystems Charts.
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Jun 2019 to Jun 2020 Click Here for more T2 Biosystems Charts.